Addex Therapeutics Ltd (ADXN)
6.87
0.36 (5.53%)
At close: Apr 10, 2025, 3:26 PM
5.53% (1D)
| Bid | 6.93 |
| Market Cap | 5.63M |
| Revenue (ttm) | 557.48K |
| Net Income (ttm) | 5.4M |
| EPS (ttm) | -23.56 |
| PE Ratio (ttm) | -0.29 |
| Forward PE | -152.2 |
| Analyst | Buy |
| Ask | 7.6 |
| Volume | 3 |
| Avg. Volume (20D) | 13,795 |
| Open | 6.91 |
| Previous Close | 6.51 |
| Day's Range | 6.87 - 6.91 |
| 52-Week Range | 6.51 - 26.59 |
| Beta | 1.97 |
About ADXN
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX7...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 12, 2020
Employees 23
Stock Exchange NASDAQ
Ticker Symbol ADXN
Analyst Forecast
According to 1 analyst ratings, the average rating for ADXN stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 336.69% from the latest price.
Stock Forecasts4 months ago
-18.65%
Addex Therapeutics shares are trading lower. The c...
Unlock content with
Pro Subscription
6 months ago
+7.96%
Addex Therapeutics shares are trading higher after the company reported H2 financial results.
